Zactima - Tyrosine Kinase Inhibitor for Treatment of Lung Cancer
Key Data:
Drug (brand / generic)
Zactima (ZD6474)
Company / licensee
AstraZeneca
Therapy class
TKI
Product description
Dual-acting TKI that targets VEGF receptor-2 (KDR) and EGFR
Current indication
NSCLC
Market sector
Oncology
Development status
Phase III
